

MARKET REPORT



EPIOMIC EPIDEMIOLOGY SERIES: ACUTE DECOMPENSATED HEART FAILURE FORECAST IN 12 MAJOR MARKETS 2017-2027

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



EPIOMIC EPIDEMIOLOGY SERIES: ACUTE DECOMPENSATED HEART FAILURE FORECAST IN 12 MAJOR MARKETS 2017-2027

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

EPIOMIC EPIDEMIOLOGY SERIES: ACUTE DECOMPENSATED HEART FAILURE FORECAST IN 12 MAJOR MARKETS 2017-2027

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Acute Decompensated Heart Failure in 12 Major Markets

Acute decompensated heart failure (ADHF), a sub-set of chronic heart failure (CHF), is a life-threatening episode during which the heart is not able to supply sufficient blood flow to the body. This requires urgent medical attention. The condition is divided into two subtypes: ADHF with reduced (ADHF-REF) and preserved (ADHF-PEF) ejection fraction. HF is characterized by dyspnoea at rest or on exertion and worsening fluid retention, apparent as lung congestion and/or swollen ankles and legs.

This report provides the current prevalent population for ADHF across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Japan, China, Russia, Brazil, India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, ADHF-REF and ADHF-PEF patients have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot. Moreover, a forecast of ADHF patient populations demonstrating main comorbidities has been included.

Main co-morbidities for ADHF include:

- Diabetes
- COPD
- Anaemia
- Atrial fibrillation
- Coronary artery disease

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

- Able to quantify patient populations in global ADHF market to target the development of future products, pricing strategies and launch plans.
- Gain further insight into the prevalence of the subdivided types of ADHF and identify patient segments with high potential.
- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
- Provide a level of understanding on the impact from specific co-morbid conditions on ADHF prevalent population.

- Identify sub-populations within ADHF which require treatment.
- Gain an understanding of the specific markets that have the largest number of ADHF patients.

Additional Details

Publisher : Black Swan Analysis

Reference : ADHF0011017

Number of Pages : 53

Report Format : PDF

Publisher Information :



Black Swan Analysis, founded in 2007, is a unique analysis practice that provides robust valuations and commercialisation plans to optimise products in the healthcare industry. We know what it takes to succeed in this industry -we've seen what works and what doesn't and we are committed to bringing insight and high quality solutions to our clients. In doing so we help them meet the many challenges of today's complex healthcare marketplace.

The Black Swan team has a unique skill set: the ability to develop dynamic market forecasts and interactive patient flow models using a wide range of data including complex pathological and epidemiological information. As pharmaceutical and healthcare companies are challenged to deliver more specific targets that align with unmet medical needs. These modelling approaches are more commercially focused to meet the requirements of a changing healthcare environment.

We have the capability to provide an immediate and 'hands-on' approach with every client and where the right internal expertise is leveraged we can help find your optimal solution. Using our bespoke methodologies and frameworks we seek to assess the most challenging valuations.

The valuation outputs we generate can be easily integrated with any in-house existing financial systems, presentation styles or platforms that may be currently operational. This ensures a faster uptake within the business, enabling resources to be re-directed towards implementing the outputs and leveraging new information.

Our philosophy at Black Swan is to create the right environment using inclusive dialogues and collaboration that

enable us to generate outputs that make business decisions clear. Our goal is to provide an unparalleled level of satisfaction and quality for our clients.

Table Of Contents for EPIOMIC EPIDEMIOLOGY SERIES: ACUTE DECOMPENSATED HEART FAILURE FORECAST IN 12 MAJOR MARKETS 2017-2027 [Report Updated: 01-1- -2017]

- Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Acute Decompensated Heart Failure in 12 Major Markets
Acute decompensated heart failure (ADHF), a sub-set of chronic heart failure (CHF), is a life-threatening episode during which the heart is not able to supply sufficient blood flow to the body. This requires urgent medical attention. The condition is divided into two subtypes: ADHF with reduced (ADHF-REF) and preserved (ADHF-PEF) ejection fraction. HF is characterized by dyspnoea at rest or on exertion and worsening fluid retention, apparent as lung congestion and/or swollen ankles and legs. This report provides the current prevalent population for ADHF across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Japan, China, Russia, Brazil, India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. Providing a value-added level of insight from the analysis team at Black Swan, ADHF-REF and ADHF-PEF patients have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot. Moreover, a forecast of ADHF patient populations demonstrating main comorbidities has been included. Main co-morbidities for ADHF include: • Diabetes • COPD • Anaemia • Atrial fibrillation • Coronary artery disease
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy • Able to quantify patient populations in global ADHF market to target the development of future products, pricing strategies and launch plans. • Gain further insight into the prevalence of the subdivided types of ADHF and identify patient segments with high potential. • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries. • Provide a level of understanding on the impact from specific co-morbid conditions on ADHF prevalent population. • Identify sub-populations within ADHF which require treatment. • Gain an understanding of the specific markets that have the largest number of ADHF patients.

List Of Tables in EPIOMIC EPIDEMIOLOGY SERIES: ACUTE DECOMPENSATED HEART FAILURE FORECAST IN 12 MAJOR MARKETS 2017-2027 [Report Updated: 01-1-2017]

CONTENTS

LIST OF TABLES AND FIGURES

INTRODUCTION

CAUSE OF THE DISEASE

RISK FACTORS & PREVENTION

DIAGNOSIS OF THE DISEASE

VARIATION BY GEOGRAPHY/ETHNICITY

DISEASE PROGNOSIS & CLINICAL COURSE

KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE

METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS

TOP-LINE PREVALENCE FOR ACUTE DECOMPENSATED HEART FAILURE

ACUTE DECOMPENSATED HEART FAILURE WITH REDUCED EJECTION FRACTION

COMORBID CONDITIONS OF ADHF-REF PATIENTS

ACUTE DECOMPENSATED HEART FAILURE WITH PRESERVED EJECTION FRACTION

COMORBID CONDITIONS OF ADHF-PEF PATIENTS

ABBREVIATIONS USED IN THE REPORT

OTHER BLACK SWAN ANALYSIS PUBLICATIONS

BLACK SWAN ANALYSIS ONLINE PATIENT-BASED DATABASES

PATIENT-BASED OFFERING

ONLINE PRICING DATA & PLATFORMS

REFERENCES

APPENDIX

LIST OF TABLES AND FIGURES

Table 1. Causes and Precipitating Factors of Acute Heart Failure

Table 2. Classification and Common Clinical Characteristics of Patients with Acute Heart Failure

Table 3. NYHA Classification of Heart Failure

Table 4. Clinical-hemodynamic profiles of heart failure (following Stevenson et al.)

Table 5. Prevalence of Acute Decompensated Heart Failure, total (000s)

Table 6. Prevalence of Acute Decompensated Heart Failure, males (000s)

Table 7. Prevalence of Acute Decompensated Heart Failure, females (000s)

Table 8. Prevalence of ADHF-REF, total (000s)

Table 9. Prevalence of ADHF-REF, males (000s)

Table 10. Prevalence of ADHF-REF, females (000s)

Table 11. ADHF-REF Patients with Diabetes, total (000s)

Table 12. ADHF-REF Patients with COPD, total (000s)

Table 13. ADHF-REF Patients with Anaemia, total (000s)

Table 14. ADHF-REF Patients with Atrial Fibrillation, total (000s)

Table 15. ADHF-REF Patients with Coronary Artery Disease, total (000s)

Table 16. Prevalence of ADHF-PEF, total (000s)

Table 17. Prevalence of ADHF-PEF, males (000s)

Table 18. Prevalence of ADHF-PEF, females (000s)

Table 19. ADHF-PEF Patients with Diabetes, total (000s)

Table 20. ADHF-PEF Patients with COPD, total (000s)

Table 21. ADHF-PEF Patients with Anaemia, total (000s)

Table 22. ADHF-PEF Patients with Atrial Fibrillation, total (000s)

Table 23. ADHF-PEF Patients with Coronary Artery Disease, total (000s)

Table 24. Abbreviations and Acronyms used in the report

Table 25. USA Prevalence of ADHF by 5-yr age cohort, males (000s)

Table 26. USA Prevalence of ADHF by 5-yr age cohort, females (000s)

Table 27. Canada Prevalence of ADHF by 5-yr age cohort, males (000s)

Table 28. Canada Prevalence of ADHF by 5-yr age cohort, females (000s)

Table 29. France Prevalence of ADHF by 5-yr age cohort, males (000s)

Table 30. France Prevalence of ADHF by 5-yr age cohort, females (000s)

Table 31. Germany Prevalence of ADHF by 5-yr age cohort, males (000s)

Table 32. Germany Prevalence of ADHF by 5-yr age cohort, females (000s)

- Table 33. Italy Prevalence of ADHD by 5-yr age cohort, males (000s)
- Table 34. Italy Prevalence of ADHD by 5-yr age cohort, females (000s)
- Table 35. Spain Prevalence of ADHD by 5-yr age cohort, males (000s)
- Table 36. Spain Prevalence of ADHD by 5-yr age cohort, females (000s)
- Table 37. UK Prevalence of ADHD by 5-yr age cohort, males (000s)
- Table 38. UK Prevalence of ADHD by 5-yr age cohort, females (000s)
- Table 39. Japan Prevalence of ADHD by 5-yr age cohort, males (000s)
- Table 40. Japan Prevalence of ADHD by 5-yr age cohort, females (000s)
- Table 41. China Prevalence of ADHD by 5-yr age cohort, males (000s)
- Table 42. China Prevalence of ADHD by 5-yr age cohort, females (000s)
- Table 43. Russia Prevalence of ADHD by 5-yr age cohort, males (000s)
- Table 44. Russia Prevalence of ADHD by 5-yr age cohort, females (000s)
- Table 45. Brazil Prevalence of ADHD by 5-yr age cohort, males (000s)
- Table 46. Brazil Prevalence of ADHD by 5-yr age cohort, females (000s)
- Table 47. India Prevalence of ADHD by 5-yr age cohort, males (000s)
- Table 48. India Prevalence of ADHD by 5-yr age cohort, females (000s)

List Of Figures, Charts and Diagrams in EPIOMIC EPIDEMIOLOGY SERIES: ACUTE DECOMPENSATED HEART FAILURE FORECAST IN 12 MAJOR MARKETS 2017-2027 [Report Updated: 01-10-2017]

See List of Tables for the Figures

How to Buy...

EPIOMIC EPIDEMIOLOGY SERIES: ACUTE DECOMPENSATED HEART FAILURE FORECAST IN 12 MAJOR MARKETS 2017-2027 [Report Updated: 01-10-2017]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/125175>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$5000** | Single User Price
- \$7500** | Site License Price
- \$9000** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.